{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:34:54Z","timestamp":1794339294630,"version":"4.9.0"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Cancer-related hypercalcemia is a common finding typically seen in patients with advanced cancer and occurs in about 20 to 30 percent of cases. The most common cause of hypercalcemia in hospitalized patients is hypercalcemia due to malignancy.This clinical problem is seen in patients with both solid tumors and patients with hematologic malignancies. Hypercalcemia is associated with a poor prognosis in oncology patients. This pathologic condition can occur due to many different mechanisms but is usually caused by abnormal calcium use resulting from bone resorption, intestinal absorption, or renal excretion. Hypercalcemia may present with a wide range of symptoms ranging from gastrointestinal system symptoms to neurologic symptoms. Timely diagnosis and initiation of treatment by the physician significantly reduce the risk of complications. Treatment aims to decrease serum calcium by increasing calciuresis, decreasing bone resorption, and decreasing intestinal calcium absorption. The mainstays of treatment are IV hydration, bisphosphonates and calcitonin, denosumab, and in some patients, prednisone, and cinacalcet. Patients with underlying advanced kidney disease and refractory severe hypercalcemia should be evaluated for hemodialysis. Every physician dealing with oncology patients should know the fastest and most effective management of hypercalcemia. We aimed to contribute in this sense.<\/jats:p>","DOI":"10.3389\/fendo.2023.1039490","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T01:46:45Z","timestamp":1679449605000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["Cancer-related hypercalcemia and potential treatments"],"prefix":"10.3389","volume":"14","author":[{"given":"Elvina","family":"Almuradova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Cicin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2015.10.012","article-title":"Prevalence of hypercalcemia of malignancy among cancer patients in the UK: analysis of the clinical practice research datalink database","volume":"39","author":"Jick","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1980.01380060012004","article-title":"Incidence of hypercalcemia and malignant neoplasm","volume":"115","author":"Burt","year":"1980","journal-title":"Arch Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2012.04.025","article-title":"Investigation of hypercalcemia","volume":"45","author":"Endres","year":"2012","journal-title":"Clin Biochem"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4103\/1947-2714.170600","article-title":"Hypercalcemia of malignancy: An update on pathogenesis and management","volume":"7","author":"Mirrakhimov","year":"2015","journal-title":"N Am J Med Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S83681","article-title":"Hypercalcemia of malignancy and new treatment options","volume":"11","author":"Sternlicht","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"B6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1159\/000188907","article-title":"Calcium-free hemodialysis for the management of hypercalcemia","volume":"72","author":"Koo","year":"1996","journal-title":"Nephron"},{"key":"B7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/sj.ki.5000169","article-title":"Coordinated control of renal Ca2+ handling","volume":"69","author":"Lambers","year":"2006","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10330","article-title":"Mechanisms of intestinal calcium absorption","volume":"88","author":"Bronner","year":"2003","journal-title":"J Cell Biochem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2142","article-title":"Parathyroid hormone-related protein: An update","volume":"97","author":"Wysolmerski","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","first-page":"680","article-title":"Mechanisms of cancer-induced hypercalcemia","volume":"67","author":"Rosol","year":"1992","journal-title":"Lab Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00543","article-title":"Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone","volume":"12","author":"Clines","year":"2005","journal-title":"EndocrRelat Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199004193221603","article-title":"Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer","volume":"322","author":"Burtis","year":"1990","journal-title":"New Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-10-4-476","article-title":"Parathyroid hormone-like proteins: biochemical responses and receptor interactions","volume":"10","author":"Orloff","year":"1989","journal-title":"Endocr Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-10-807","article-title":"Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia","volume":"111","author":"Budayr","year":"1989","journal-title":"Ann Intern Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472","article-title":"TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling","volume":"71","author":"Johnson","year":"2011","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650061413","article-title":"Differential diagnosis of hypercalcemia","author":"Lafferty","year":"1991","journal-title":"J Bone Miner Res"},{"key":"B17","article-title":"Metabolizmus vitaminu d [Vitamin d metabolism]","volume":"58","author":"Kulda","year":"2012","journal-title":"Vnitr Lek"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.27","article-title":"Phosphate and FGF-23","volume":"79","author":"J\u00fcppner","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1557::AID-CNCR5>3.0.CO;2-H","article-title":"Mechanisms of bone lesions in multiple myeloma and lymphoma","volume":"80","author":"Roodman","year":"1997","journal-title":"Cancer"},{"key":"B20","first-page":"1672","article-title":"Hypercalcemia in the blastic phase of chronic myeloid leukemia associated with elevated parathyroid hormone-related protein","volume":"7","author":"Seymour","year":"1993","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4158\/EP.15.3.234","article-title":"Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone\u2013related peptide and 1,25-dihydroxyvitamin d in a patient with metastatic renal cell carcinoma","volume":"15","author":"Shivnani","year":"2009","journal-title":"Endocr Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2019.01.003","article-title":"Gynecological neoplasms associated with paraneoplastic hypercalcemia","volume":"36","author":"Lim","year":"2019","journal-title":"Semin Diagn Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogc.2018.05.004","article-title":"Two cases of hypercalcemia in pediatric ovarian dysgerminoma","volume":"41","author":"Hosseini","year":"2019","journal-title":"J Obstet Gynaecol Can"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"New Engl J Med"},{"key":"B25","volume-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","author":"Horwitz","year":"2008"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.671","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-008055232-3.60633-6","article-title":"Hypercalcemia","author":"Yee","year":"2007","journal-title":"xPharm: Compr Pharmacol Reference"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa b ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.metabol.2017.11.012","article-title":"Biology and treatment of myeloma related bone disease","volume":"80","author":"Terpos","year":"2018","journal-title":"Metabolism"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.011155","article-title":"Cancer-related hypercalcemia","volume":"12","author":"Goldner","year":"2016","journal-title":"J Oncol Pract"},{"key":"B31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/jcb.10613","article-title":"Activin a stimulates IkappaB-alpha\/NFkappaB and RANKexpression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors","volume":"90","author":"Sugatani","year":"2003","journal-title":"J Cell Biochem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90074.x","article-title":"Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma","volume":"64","author":"Abildgaard","year":"2000","journal-title":"Eur J Haematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S1359-6349(06)70202-6","article-title":"Denosumab is a selective inhibitor of human receptor activator of NF-KB ligand that blocks osteoclast formation","volume":"4","author":"Elliott","year":"2006","journal-title":"Vitro vivo. Eur J Cancer Suppl"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-68-5-976","article-title":"Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia","volume":"68","author":"Yoshimoto","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1210\/jc.2005-2095","article-title":"Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene","volume":"91","author":"VanHouten","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1507\/endocrj.ej12-0406","article-title":"Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature","volume":"60","author":"Nakajima","year":"2013","journal-title":"Endocr J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4158\/EP.1.6.390","article-title":"Pseudohypercalcemia in an elderly patient with multiple myeloma: report of a case and review of literature","volume":"1","author":"Schwab","year":"1995","journal-title":"Endocr Pract"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/35888","article-title":"Mello CC.Potent and specific genetic interference by double-stranded RNAin caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2015.1047506","article-title":"Quality and outcomes of treatment of hypercalcemia of malignancy","volume":"33","author":"Wright","year":"2015","journal-title":"Cancer Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.433","article-title":"The risk of cancer in primary care patients with hypercalcaemia: A cohort study using electronic records","volume":"111","author":"Hamilton","year":"2014","journal-title":"Br J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110918","article-title":"Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. role of prostaglandins, renin-angiotensin system, and calcium","volume":"71","author":"Levi","year":"1983","journal-title":"J Clin Invest"},{"key":"B44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3810\/pgm.2004.04.1486","article-title":"Understanding hypercalcemia","volume":"115","author":"Inzucchi","year":"2004","journal-title":"Its Metab basis signs symptoms. Postgrad Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-2197.1998.tb04719.x","article-title":"Pancreatitis and primary hyperparathyroidism: forty cases","volume":"68","author":"Carnaille","year":"1998","journal-title":"Aust N Z J Surg"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198102000-00019","article-title":"Primary hyperparathyroidism and the gastrointestinal tract","volume":"74","author":"Gardner","year":"1981","journal-title":"South Med J"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1978.tb14879.x","article-title":"Reversible renal failure caused by hypercalcemia","volume":"203","author":"Lins","year":"1978","journal-title":"A retrospective study. Acta Med Scand"},{"key":"B48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/00005792-198803000-00002","article-title":"The syndrome of distal renal tubular acidosis","volume":"67","author":"Caruana","year":"1988","journal-title":"Clin Lab findings 58 cases. Med Baltimore"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1964.tb115035.x","article-title":"Hypercalcaemic nephropathy","volume":"2","author":"Parfitt","year":"1964","journal-title":"Med J Aust"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.52.0444","article-title":"Posterior reversible encephalopathy syndrome due to hypercalcemia associated with parathyroid hormone-related peptide: a case report and review of the literature","volume":"52","author":"Nakajima","year":"2013","journal-title":"Intern Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3487","article-title":"Posterior reversible encephalopathy syndrome due to malignant hypercalcemia: physiopathological considerations","volume":"99","author":"Camara-Lemarroy","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","volume-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism, 6","author":"Shane","year":"2006"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2004.04.006","article-title":"Electrocardiographic manifestations: electrolyte abnormalities","volume":"27","author":"Diercks","year":"2004","journal-title":"J Emerg Med"},{"key":"B54","article-title":"Ventricular fibrillation in hypercalcaemic crisis due to primary hyperparathyroidism","volume":"62","author":"Kiewiet","year":"2004","journal-title":"Neth J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21489","article-title":"Hypercalcemia and cancer: Differential diagnosis and treatment","volume":"68","author":"Zagzag","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B56","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.cca.2011.01.004","article-title":"Ionized calcium","volume":"412","author":"Baird","year":"2011","journal-title":"Clin Chim Acta"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3109\/10408363.2014.970266","article-title":"Laboratory approaches for the diagnosis and assessment of hypercalcemia","volume":"52","author":"Meng","year":"2015","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-48-3-393","article-title":"Relationship of free and total calcium in hypercalcemic conditions","volume":"48","author":"Ladenson","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08173.x","article-title":"Haematological emergencies managing hypercalcaemia in adults and children with haematological disorders","volume":"149","author":"Sargent","year":"2010","journal-title":"Br J Haematol"},{"key":"B60","article-title":"Abeloff's clinical oncology, 4th edition part II \u2013 problems common to cancer and its therapy section d \u2013 metabolic and paraneoplastic syndromes","author":"Morton","year":"2020","journal-title":"Chapter 48 \u2013 Hypercalcemia"},{"key":"B61","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1210\/jcem.76.3.8445039","article-title":"Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin d serum levels in hypercalcemia of malignancy","volume":"76","author":"Schilling","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"B62","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0002-9343(97)89515-0","article-title":"Parathyroid-hormone-related peptide in hematologic malignancies","volume":"100","author":"Kremer","year":"1996","journal-title":"Am J Med"},{"key":"B63","article-title":"Familial hypocalciuric hypercalcemia. [Updated 2022 jul 19]","volume-title":"StatPearls","author":"Afzal","year":"2022"},{"key":"B64","doi-asserted-by":"publisher","first-page":":11","DOI":"10.13129\/1828-6550\/APMB.109.2.2021.CCS3","article-title":"Familial hypocalciuric hypercalcemia: grey zones of the differential diagnosis from primary hyperparathyroidism: a case report","volume":"109","author":"Ruggeri","year":"2021","journal-title":"APMB"},{"key":"B65","first-page":"1445","article-title":"Clinical review 51: Management of hypercalcemia","volume":"77","author":"Bilezikian","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJM199204303261806","article-title":"Management of acute hypercalcemia","volume":"326","author":"Bilezikian","year":"1992","journal-title":"N Engl J Med"},{"key":"B67","first-page":"473","article-title":"Rehydration in the treatment of severe hypercalcaemia","volume":"50","author":"Hosking","year":"1981","journal-title":"Q J Med"},{"key":"B68","first-page":"99","article-title":"Evaluation and therapy of hypercalcemia","volume":"108","author":"Khoury","year":"2011","journal-title":"Mo Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"83","DOI":"10.14310\/horm.2002.1225","article-title":"Medical treatment of hypercalcaemia","volume":"8","author":"Makras","year":"2009","journal-title":"Hormones (Athens)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-374602-3.00053-5","article-title":"Chapter 53 - calcitonin: History, physiology, pathophysiology and therapeutic applications","author":"Wimalawansa","year":"2010","journal-title":"Osteoporosis Men (Second Edition) Effects Gender Skeletal Health"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6910312","article-title":"RANKL\/RANK\/OPG pathway: A mechanism involved in exercise-induced bone remodeling","volume":"6910312","author":"Tobeiha","year":"2020","journal-title":"BioMed Res Int"},{"key":"B72","doi-asserted-by":"publisher","first-page":"192","DOI":"10.7326\/0003-4819-95-2-192","article-title":"Calcitonin as a drug","volume":"95","author":"Deftos","year":"1981","journal-title":"Ann Intern Med"},{"key":"B73","first-page":"2375","article-title":"Human calcitonin in neoplastic hypercalcemia","volume":"17","author":"Chevallier","year":"1988","journal-title":"Results prospective randomized trial. Presse Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1056\/NEJM198101293040505","article-title":"Calcitonin: physiology and pathophysiology","volume":"304","author":"Austin","year":"1981","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1007\/BF02553290","article-title":"Salmon calcitonin in the acute management of hypercalcemia","author":"Wisneski","year":"1990","journal-title":"Calcif Tissue Int"},{"key":"B76","article-title":"Bisphosphonates in bone disease","volume-title":"From the laboratory to the patient, 4th edn","author":"Fleisch","year":"2000"},{"key":"B77","article-title":"Bisphosphonate antiresorptive structure\u2013activity relationships","volume-title":"Russell RGG (eds) bisphosphonate on bones","author":"Ebetino","year":"1995"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1998.13.11.1668","article-title":"Heterocycle-containing bisphosphonates cause apoptosis and inhibit boneresorption by preventing protein prenylation: evidence fromstructure-activity relationships in J774 macrophages","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601643103","article-title":"The molecularmechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/s0140-6736(89)91791-1","article-title":"Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia","volume":"2","author":"Ralston","year":"1989","journal-title":"Lancet"},{"key":"B82","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0093-7754(01)90261-1","article-title":"Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program","volume":"28","author":"Major","year":"2001","journal-title":"Semin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the bone working group of the international myeloma working group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000094676","article-title":"Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports","volume":"116","author":"Henrich","year":"2006","journal-title":"Acta Haematol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30365-7","article-title":"Vitamin d metabolite-mediated hypercalcemia","volume":"18","author":"Adams","year":"1989","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07950.x","article-title":"Corticosteroid-induced clinical adverse events: Frequency, risk factors and patient\u2019s opinion","volume":"157","author":"Fardet","year":"2007","journal-title":"Br J Dermatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12517","article-title":"Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures","volume":"13","author":"Pittman","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3031","article-title":"Denosumab for management of parathyroid carcinoma-mediated hypercalcemia","volume":"99","author":"Vellanki","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.794988","article-title":"Denosumab for the treatment of hypercalcemia in a patient with parathyroid carcinoma: A case report","volume":"12","author":"Roukain","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0487","article-title":"Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift","volume":"10","author":"O'Callaghan","year":"2021","journal-title":"Endocr Connect"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10114","article-title":"Recurrent metastasized parathyroid carcinoma-Long-Term remission after combined treatments with surgery, radiotherapy, cinacalcet, zoledronic acid, and temozolomide","volume":"3","author":"Storvall","year":"2018","journal-title":"JBMR Plus"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111353","article-title":"Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia","volume":"73","author":"Warrell","year":"1984","journal-title":"J Clin Invest"},{"key":"B98","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/00130404-200601000-00009","article-title":"Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia","volume":"12","author":"Cvitkovic","year":"2006","journal-title":"Cancer J"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-5-669","article-title":"Gallium nitrate for acute treatment of cancer-related hypercalcemia. a randomized, double-blind comparison to calcitonin","volume":"108","author":"Warrell","year":"1988","journal-title":"Ann Int Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-005-0678-4","article-title":"Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage","volume":"24","author":"Arumugam","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/0169-6009(90)90106-P","article-title":"Gallium inhibits bone resorption by a direct effect on osteoclasts","volume":"8","author":"Hall","year":"1990","journal-title":"Bone miner"},{"key":"B102","article-title":"Renal replacement therapy as a treatment for severe refractory hypercalcemia","volume":"39","author":"Pittaway","year":"2014","journal-title":"Minerva Endocrinol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/s0272-6386(97)90044-5","article-title":"Correction of hypercalcemia and hypophosphatemia by hemodialysis using a conventional, calcium-containing dialysis solution enriched with phosphorus","volume":"29","author":"Leehey","year":"1997","journal-title":"Am J Kidney Dis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1039490\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T01:46:56Z","timestamp":1679449616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1039490\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":103,"alternative-id":["10.3389\/fendo.2023.1039490"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1039490","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"article-number":"1039490"}}